The stock fell dramatically despite blowout efficacy data because of a perceived cancer risk. A deeper dive shows this risk was overstated due to including non-cancers, common skin cancers, and failing to account for background cancer rates, creating a significant dislocation between price and fundamentals.
While "clinical remission" is the primary endpoint for FDA approval, many gastroenterologists find "endoscopic remission"—the complete healing of the colon visible via colonoscopy—to be a more reliable and objective measure of a drug's true efficacy. Abivax's drug showed unprecedented results on this metric.
Management included raw cancer case numbers in their press release without proper framing or explanation. This led investors to perceive a problem that, upon expert review, wasn't there. This highlights the critical importance of communication strategy when releasing complex clinical data.
In Abivax's trial, placebo patients dropped out due to lack of efficacy, meaning they were monitored for less time than patients on the effective drug. This "adverse event capture" bias can falsely make the drug arm appear to have a higher rate of side effects, a subtle but critical data interpretation error.
The market's fear of a cancer risk was based solely on the one-year Phase 3 data. A more thorough analysis would have included the seven-year Phase 2 study, which represented a much larger safety dataset in terms of patient-years and showed no concerning signals. This highlights a common investor error.
The speaker notes that despite publishing a mathematically-backed thesis showing Abivax's trial was guaranteed to succeed, the stock traded down. This demonstrates that even with clear, public data, the biotech market can be inefficient, rewarding investors who perform deep, fundamental analysis instead of following sentiment.
Even in a worst-case scenario where Abivax's drug gets a black box warning for cancer, it would still be a multi-billion dollar product. This is because its efficacy beats the main competitor, Renvoke, which already has five black box warnings. The drug's value is resilient due to its superior profile.
After the stock crashed on cancer fears, management accelerated the release of a larger safety dataset from October to June. This move, aimed at restoring confidence, suggests they believe the additional data will exonerate the drug, showing how companies must react dynamically to severe market misinterpretations.
Despite positive clinical data, Nectar's stock has declined significantly. This is likely due to non-scientific factors, such as an ongoing lawsuit against Eli Lilly. Some specialist investors are avoiding the stock until this legal uncertainty, which is outside their analytical wheelhouse, is resolved.